SHSandra Herranz-Antolín

Sandra Herranz-Antolín

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sandra Herranz-Antolín has a total of 131 co-authors. Here are the top co-authors by number of shared publications:

  • Cristina Tejera-Pérez

    Department of Endocrinology and Nutrition, University Hospital Complex of Ferrol, A Coruña, Spain; Epigenomics Group in Endocrinology and Nutrition, Epigenomics Unit, Health Research Institute of Santiago de Compostela, University Hospital Complex of Santiago de Compostela, Santiago de Compostela, Spain

    3 shared publications
  • Gema López-Gallardo

    Virgen del Rocío University Hospital, Sevilla, Spain

    3 shared publications
  • Javier González-López

    Sección de Endocrinología y Nutrición, Hospital Virgen de la Luz, Cuenca, Spain

    3 shared publications
  • Julia Sastre

    Servicio de Endocrinología y Nutrición, Complejo Hospitalario Universitario de Toledo, Toledo, Spain

    3 shared publications
  • María Covadonga López-Virgos

    Internal Medicine Department, University Hospital of Guadalajara, Guadalajara, Spain

    3 shared publications
  • Miguel Torralba

    Instituto de Investigación Sanitaria de Castilla La Mancha (IDISCAM), Toledo, Spain

    3 shared publications

Latest Publications

  • Open Access

    Association Between the GMI / HbA1c Ratio and Microvascular Complications in Type 1 Diabetes: A Multicenter Cross‐Sectional Study

    by Sandra Herranz‐Antolín, María Asunción Martínez‐Brocca, Gloria Cánovas‐Molina, Aurora Aragón‐Alonso, Miguel Brito‐Sanfiel, Jose Ignacio Martínez‐Montoro, Virginia Bellido, Sharona Azriel, María del Carmen López‐García, Cristina Tejera, et al.

    Objective: To clarify whether the glucose management indicator (GMI)/glycated haemoglobin (HbA1c) ratio (GMI/HbA1c ratio) is an independent predictor of microvascular complications in Type 1 diabetes (T1D). Design and Methods: Multicentre, cross‐sectional, observational study including subjects with T1D with at least 5 years of evolution, users of continuous glucose monitoring (CGM) with a coverage ≥ 80% 56 days prior to HbA1c. Logistic regression models were used to identify the factors independently associated with grouped microvascular complications and ocular disease. Results: As per data, 1315 participants were included. Patients were classified into tertiles based on the GMI/HbA1c ratio. High glycators were older than intermediate and low glycators (55.4 vs. 53.4 vs. 50.8 years; p < 0.001), respectively. Differences were also observed among the three groups with regard to average glucose (156.3 vs. 161.8 vs. 166.1 mg/dL; p < 0.001), time in range (66.3% vs. 62.9% vs. 59.9%; p < 0.001), time in tight range (42.9% vs. 39.9% vs. 37.1%; p < 0.001), coefficient of variation (34.5% vs. 34.9% vs. 35.6%; p = 0.023), GMI (7% vs. 7.2% vs. 7.3%; p < 0.001) and HbA1c (8.1% vs. 7.3% vs. 6.6%; p < 0.001). In the high glycators group, the prevalence of microvascular complications was higher than in the intermediate and low glycators (38.9% vs. 28.2% vs. 23.7%; p < 0.001), respectively. Also, the prevalence of ocular disease (31% vs. 20.2% vs. 19.7%; p < 0.001), nephropathy (14.9% vs. 8.3% vs. 6.2%; p < 0.001) and polyneuropathy (10.6% vs. 6.8% vs. 3.4%; p < 0.001) was higher in high glycators, The GMI/HbA1c ratio was significantly associated with the presence of grouped microvascular complications (OR 0.71; 95% CI: 0.61–0.81; p < 0.001) and ocular disease (OR 0.71; 95% CI: 0.61–0.82; p < 0.001) after adjusting for clinical ad glucometric variables. Conclusions: The GMI/HbA1c ratio is associated with microvascular complications in this study. These results highlight the potential of this parameter in routine clinical practice for stratifying the risk of complications and for establishing individualized control goals and screening strategies.

  • Increased Glycation Ratio and Risk of Complications in Latent Autoimmune Diabetes in Adults Compared With Type 1 Diabetes Onset before 30 Years: A Cohort Study

    by Sandra Herranz-Antolín, Fernando Gómez-Peralta, Xu Yongjin, María Asunción Martínez-Brocca, Gloria Cánovas-Molina, Aurora Aragón-Alonso, Miguel Brito-Sanfiel, Jose Ignacio Martínez-Montoro, Virginia Bellido, Sharona Azriel, et al.

    Objective: To clarify the distinctions between Latent Autoimmune Diabetes in Adults (LADA) and Type 1 diabetes (T1D) diagnosed < 30 years using continuous glucose monitoring (CGM) metrics, glycation rate, and risk of complications. Design and Methods: Multicenter, cross-sectional, observational study including subjects with T1D onset < 30 years (T1D cohort) and those classified as LADA diagnosed ≥ 30 years (LADA cohort) with ≥ 80% CGM coverage 56 days prior to glycated hemoglobin (HbA1c). Logistic regression was used to model the risk of complications. Results: T1D ( n = 555) and LADA ( n = 890) showed different ages (43 vs. 58 years; P < 0.001), age at diagnosis (16 vs. 43 years; P < 0.001), diabetes duration (26.8 vs. 15.1 years; P < 0.001), HbA1c (7.2 vs. 7.3%; P = 0.017), microvascular complications (35 vs. 23%; P < 0.001), and daily total and basal insulin [0.63 vs. 0.59 U/(kg·d); P = 0.006 and 0.35 vs. 0.32 U/(kg·d); P = 0.002]. After adjusting for diabetes duration, T1D exhibited higher time below range (TBR70: 3.9 vs. 3.0%; P < 0.001; TBR54: 0.5 vs. 0.3%; P < 0.001) and variability [coefficient of variation (CV): 35.6 vs. 34.2%; P < 0.001; within-day CV: 31.4 vs. 30.3%; P < 0.001]. Personal glycation ratio was higher in LADA after adjusting for diabetes duration and body mass index (66.5 vs. 64.9%; P < 0.001). Estimated risks of macrovascular and microvascular complications were higher in LADA than in T1D [12.6% (95% CI 9.7–15) vs. 3.8% (95% CI 2.1–5.6) and 46.1% (95% CI 40.4–52.0) vs. 29.1% (95% CI 25.1–33.5)] after adjusted for diabetes duration. Conclusions: LADA cohort showed a higher glycation rate and lower time in hypoglycemia and variability. Microvascular complications were more common in T1D, but after adjusting for diabetes duration, macrovascular and microvascular risks were greater in LADA.

  • Time in Tight Range (TITR) stratified by Coefficient of Variation (CV) in a cohort of patients with type 1 Diabetes Mellitus and Multiple Daily Injections. A real-life study

    by Sandra Herranz-Antolín, Verónica Esteban-Monge, María Covadonga López-Virgos, Sofía Ramos-Garrido, Clara Coton-Batres, Silvia Lallena-Pérez, Miguel Torralba

    Objetive To analyze the Time in Tight Range (TITR) (70–140 mg/dL) and the relationship between TITR-Time in Range (TIR) and assess their possible differences according to Coefficient of Variation (CV) in a cohort of patients with type 1 Diabetes Mellitus (DM) and Multiple Daily Injections in real life. Patients and methods 355 adult users of Continuous Glucose Monitoring (CGM) with at least one HbA1c (October 1, 2023-October 1, 2024) and glucose data in the 90 days prior were included. Results Age 46.9 years (SD 13.6); 57.2% male; time of evolution 21.6 years (SD 12.6). Mean TITR was 38.4% (SD 14.6) and 20.3% had a TITR ≥ 50%. The correlation TITR-TIR was strong (β = 0.83; CI 95% 0.8–0.87; R2 Adjusted 0.89; p < 0.001) and varied according to CV [CV ≤ 36% (β = 0.88; CI 95% 0.83–0.93; R2 Adjusted 0.89; p < 0.001); CV > 36% (β = 0.84; CI 95% 0.81–0.87; R2 Adjusted 0.93; p < 0.001)]. The cutoff value for TIR to discriminate TITR ≥ 50% varied according to CV [(CV ≤ 36% 75.9% (sensitivity 98%, specificity 94%, AUC 0.99, p < 0.001); CV > 36% 70.5% (sensitivity 100%, specificity 98%, AUC 0.99, p < 0.001)]. The variables that were independently associated with TITR in CV ≤ 36% group were TIR (β = 0.74; CI 95% 0.57–0.9; p < 0.001) and mean glucose (β = −0.11; CI 95% −0.21 to −0.01; p = 0.045). However, in CV > 36% group were time of evolution (β = 0.04; CI 95% 0.01–0.07; p = 0.008), HbA1c (β = −0.63; CI 95% −1.22 to −0.4; p = 0.036; CV (β = 0.33; CI 95% 0.24–0.41; p < 0.001) and TIR (β = 0.84; CI 95% 0.74–0.93; p < 0.001). Conclusions The correlation between TITR-TIR was strong and higher in patients with CV > 36%. Cutoff value for TIR to discriminate TITR ≥ 50% and factors that were associated with TITR also differ depending on CV. It is essential to take glycemic variability into account when interpreting metabolic control data.

  • Time in Tight Range (TITR) stratified by Time Below Range (TBR) in a cohort of patients with type 1 Diabetes Mellitus and Multiple Daily Injections. A real-life study

    by Sandra Herranz-Antolín, Sofía Ramos-Garrido, Verónica Esteban-Monge, Clara Coton-Batres, María Covadonga López-Virgos, Silvia Lallena-Pérez, Miguel Torralba

    Objetive To analyze the Time in Tight Range (TITR) (70–140 mg/dL) and assess their possible differences according to Time Below Range (TBR) in a cohort of type 1 diabetes mellitus people with Múltiple Daily Injections. Patients and methods 355 adult users of Continuous Glucose Monitoring (CGM) with at least a HbA1c during the period October 1, 2023-October 1, 2024, and glucose data in the 90 days prior were included. Results Age 46.9 years (SD 13.6); 57.2% male; time of evolution 21.6 years (SD 12.6). Mean TITR was 38.4% (SD 14.6) and 20.3% had a TITR ≥ 50%. The correlation TITR-TIR was strong (β = 0.83; CI 95% 0.8–0.87; R [2] Adjusted 0.89; p < 0.001) and varied according to TBR [TBR < 4% group (β = 0.81; CI 95% 0.78 to 0.85; R [2] Adjusted 0.9; p < 0.001) vs. TBR ≥ 4% (β = 0.9; CI 95% 0.86 to 0.94; R [2] Adjusted 0.93; p < 0.001)]. The variables independently associated with TITR in patient with TBR < 4% were HbA1c (β = -9.58; CI 95% -10.88 to -8.29; p < 0.001) and Coefficient of Variation (CV) (β = -0.38; CI 95% -0.66 to -0.11; p = 0.007). However, in those with TBR ≥ 4% were male gender (β = 2.86; CI 95% 0.26 to 5.45; p = 0.031), HbA1c (β = -7.53; CI 95% -9.1 to -5.96; p < 0.001) and CV (β = -0.69; CI 95% -1.01 to -0.37; p < 0.001). Conclusions The correlation between TITR and TIR and the factors that were independently associated with TITR differ depending on the TBR.

  • CANTCAM project (ANaplastic Thyroid Carcinoma in CAstilla-La Mancha). Multicenter retrospective study

    by Sandra Herranz-Antolín, Rosa Quílez-Toboso, Jesús Moreno-Fernández, Javier González-López, María López-Iglesias, Julia Sastre

  • Glycemic Risk Index in a Cohort of Patients with Type 1 Diabetes Mellitus Stratified by the Coefficient of Variation: A Real-Life Study

    by Sandra Herranz-Antolín, Clara Coton-Batres, María Covadonga López-Virgos, Verónica Esteban-Monge, Visitación Álvarez-De Frutos, Leonel Pekarek, Miguel Torralba

    Objective: : To analyze the Glycemic Risk Index (GRI) and assess their possible differences according to coefficient of variation (CV) in a cohort of real-life type 1 diabetes mellitus (DM) patient users of intermittently scanned continuous glucose monitoring (isCGM). Patients and Methods: : In total, 447 adult users of isCGM with an adherence ≥70% were included in a cross-sectional study. GRI was calculated with its hypoglycemia (CHypo) and hyperglycemia (CHyper) components. Multivariate linear regression analysis was performed to evaluate the factors associated with GRI. Results: Mean age was 44.6 years (standard deviation [SD] 13.7), 57.7% being male; age of DM onset was 24.5 years (SD 14.3) and time of evolution was 20.6 years (SD 12.3). In patients with CV >36% (52.8%) versus CV ≤36% (47.2%), differences were observed in relation to GRI (18.8% [SD 1.9]; P < 0.001), CHypo (2.9% [SD 0.3]; P < 0.001), CHyper (6.3% [SD 1.4]; P < 0.001), and all classical glucometric parameters except time above range level 1. The variables that were independently associated with GRI in patient with CV >36% were time in range (TIR) (β = −1.49; confidence interval [CI:] 95% −1.63 to −1.37; P < 0.001), glucose management indicator (GMI) (β = −7.22; CI: 95% −9.53 to −4.91; P < 0.001), and CV (β = 0.85; CI: 95% 0.69 to 1.02; P < 0.001). However, in patients with CV ≤36%, the variables were age (β = 0.15; CI: 95% 0.03 to 0.28; P = 0.019), age of onset (β = −0.15; CI: 95% −0.28 to −0.02; P = 0.023), TIR (β = −1.35; CI: 95% −1.46 to −1.23; P < 0.001), GMI (β = −6.67; CI: 95% −9.18 to −4.15; P < 0.001), and CV (β = 0.33; CI: 95% 0.11 to 0.56; P = 0.004). Conclusions: In this study, the factors independently associated with metabolic control according to GRI are modified by glycemic variability.


  • Open Access

    Biomarkers of oxidation, inflammation and intestinal permeability in persons with diabetes mellitus with parenteral nutrition: A multicenter randomized trial

    by Virginia Soria-Utrilla, Corina Verónica Sasso, Silvana Yanina Romero-Zerbo, Antonio Adarve-Castro, Rafael López-Urdiales, Sandra Herranz-Antolín, José Manuel García-Almeida, Katherine García-Malpartida, Mercedes Ferrer-Gómez, Alicia Moreno-Borreguero, et al.


  • Factors associated with Glycemia Risk Index in a cohort of patients with type 1 Diabetes Mellitus and Latent Autoimmune Diabetes In Adults (LADA)

    by Sandra Herranz-Antolín, Clara Cotón-Batres, María Covadonga López-Virgos, Verónica Esteban-Monge, Visitación Álvarez- de Frutos, Miguel Torralba

    Objective To analyze the degree of control based on classical glucometric parameters and Glycemia Risk Index (GRI) in real-life conditions in a cohort of patients with type 1 Diabetes Mellitus (DM) and Latent Autoimmune Diabetes in Adults (LADA) and to assess the factors that are associated with GRI. Patients and methods Cross-sectional study. 447 adult patients with type 1 DM and LADA users of Intermittent Continuous Glucose Monitoring (iCGM) with an adherence ≥ 70% were included. GRI was calculated with its Hypoglycemia (CHypo) and Hyperglycemia (CHyper) Components. Multivariate linear regression analysis was performed to evaluate the factors associated with GRI. Results Mean age 44.6 years (SD 13.7); 57.7% men; 83.9% type 1 DM; 16.1% LADA; time of evolution 20.6 years (SD 12.3). In patients with type 1 DM vs. LADA, differences were observed in relation to age [−11.1 years (SD 1.7)], age of onset [−21.9 years (DE 1.5)], time of evolution [11.7 years (DE 1.5)], treatment modality (p < 0.001), Time in Range (TIR) [−6.3% (SD 2.2)], Time Below Range (TBR) [1.9% (SD 0.6)], TBR level 1 (TBR1) [1.4% (SD 0.5)], Time Above Range (TAR) level 2 (TAR2) [4.7% (SD 1.3)], Coefficient of Variation (CV) [4.6% (SD 0.9)], GRI [11.3% (SD 2.8)], CHypo [1.3% (SD 0.5)] and CHyper [4.8% (SD 1.7)]. The variables that were independently associated with GRI were TIR (β = −1.34; CI 95% −1.43 to −1.25; p < 0.001), Glucose Management Indicator (GMI) (β = −5.82; CI 95% −7.59 to −4.05; p < 0.001), CV (β = 0.67; CI 95% 0.57 to 0.77; p < 0.001) and adherence to sensor usage (β = −0.16; CI 95% −1.27 to −0.06; p < 0.002). Conclusions LADA present better control according to some glucometric parameters and a low GRI. However, the type of DM is not a factor that is independently associated with GRI.


  • Prevalence of autoimmune diseases in patients with type 1 diabetes mellitus. DIACAM 1 study 2010–2020

    by Sandra Herranz-Antolín, Julia Sastre, César Gonzalvo-Díaz, Florentino Del Val-Zaballos, Jesús Moreno-Fernández, Javier González-López, Iván Quiroga-López, Gema López-Gallardo


  • Prevalencia de enfermedades autoinmunes en pacientes con diabetes mellitus tipo 1. Estudio DIACAM 1 2010-2020

    by Sandra Herranz-Antolín, Julia Sastre, César Gonzalvo-Díaz, Florentino Del Val-Zaballos, Jesús Moreno-Fernández, Javier González-López, Iván Quiroga-López, Gema López-Gallardo